摘要 |
Provided are methods employing BCL-2 for the treatment of VDAC-associated disease, wherein the methods comprise administering to a mammal a Bcl-2 protein in an amount sufficient to inhibit a VDAC-associated disease. The disclosure also provides methods for identifying a Bcl- 2 protein that inhibits a VDAC-associated disease when administered to an animal, as well as methods for increasing the effectiveness of a gene, stem cell and/or vaccine therapy involving the administration of an extracellular Bcl-2 protein, a Bcl-2 family member, and/or a fragment thereof comprising a BH4 domain. The disclosure further provides methods for treating diseases involving administering a Bcl-2 protein to a cell that has been engineered to produce exosomes comprising nucleic acid constructs engineered for selective therapeutic transfection of target cell types. |